The US FDA Grants Clearance to Alcon’s Unity VCS and Unity CS for Eye Care

Share this

The US FDA Grants Clearance to Alcon’s Unity VCS and Unity CS for Eye Care


  • The US FDA has granted 510(k) clearance to the company's cataract systems, UNITY Vitreoretinal Cataract System (VCS) and UNITY Cataract System (CS). Alcon will collect real-world data prior to the 2025 commercial launch; further worldwide regulatory submissions are planned in H2’24 with CE Mark in early 2025
  • The UNITY VCS system is developed for anterior segment (cataract removal) and posterior segment (vitreoretinal) ophthalmic surgeries. It can also be used for photocoagulation, iridotomy & trabeculoplasty procedures with an optional laser
  • The UNITY CS system is intended for anterior segment (phacoemulsification & cataract removal) ophthalmic surgery

Ref: Alcon | Image: Alcon

Related News:- Alcon Reports the Results for AR-15512 in P-III Trial for the Treatment of Dry Eye Disease

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions